Return to Today's science sparks archives

2019-01-02

Fig. 1 Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor.

Fig. 1 Lymphoma cells with BCL2/PMAIP1 coamplification are highly sensitive to BCL-2 inhibitor.
  • Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A

  • Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12034-12039.
Open Access button

2019-01-03

Fig. 1 a) Dicentric chromosomes are formed by the fusion of dysfunctional telomeres during telomere crisis.

Fig. 1 a) Dicentric chromosomes are formed by the fusion of dysfunctional telomeres during telomere crisis.
  • von Morgen P, Maciejowski J

  • Genome Med. 2018 Nov 27;10(1):89.
Open Access button

2019-01-04

Fig. 2 (A) Working group consensus on preferred end points by biologic subtype and line of therapy. (B) Hypothetical scenarios for expected postprogression survival (PPS) and choice of preferred end point.

Fig. 2 (A) Working group consensus on preferred end points by biologic subtype and line of therapy. (B) Hypothetical scenarios for expected postprogression survival (PPS) and choice of preferred end point.
  • Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA

  • J Clin Oncol. 2018 Sep 13:JCO1800242.

2019-01-07

Fig. 2 FAT1 loss and clinical resistance.

Fig. 2 FAT1 loss and clinical resistance.
  • Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S

  • Cancer Cell. 2018 Dec 10;34(6):893-905.e8.

2019-01-08

Fig. 1 Tyrosine kinase inhibitors and antibodies or antibody–drug conjugates in clinical use or under clinical investigation to target EGFR, HER2, and HER3 in EGFR-mutant lung cancers.

Fig. 1 Tyrosine kinase inhibitors and antibodies or antibody–drug conjugates in clinical use or under clinical investigation to target EGFR, HER2, and HER3 in EGFR-mutant lung cancers.
  • Fan PD, Yu HA

  • Clin Cancer Res. 2018 Nov 15;24(22):5499-5501.

2019-01-09

Fig. 1 Reliability of somatic SNVs and INDELs detected by WES and high-depth amplicon sequencing validation of variants.

Fig. 1 Reliability of somatic SNVs and INDELs detected by WES and high-depth amplicon sequencing validation of variants.
  • Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, Chagpar AB, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C

  • Cell Rep. 2018 Nov 6;25(6):1446-1457.
Open Access button

2019-01-10

Fig. 1 Chimeric Antigen Receptor (CAR) design across generations.

Fig. 1 Chimeric Antigen Receptor (CAR) design across generations.
  • Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR

  • J Immunother Cancer. 2018 Dec 4;6(1):137.
Open Access button

2019-01-11

Fig. 1 Coronal image from a whole body CT demonstrating a color-coded map of voxels with mean HU values within the range −29 and +150 (colored green on this image).

Fig. 1 Coronal image from a whole body CT demonstrating a color-coded map of voxels with mean HU values within the range −29 and +150 (colored green on this image).
  • Halpenny DF, Goncalves M, Schwitzer E, Golia Pernicka J, Jackson J, Gandelman S, Moskowitz CS, Postow M, Mourtzakis M, Caan B, Jones LW, Plodkowski AJ

  • Br J Radiol. 2018 Dec;91(1092):20180451.

2019-01-14

Fig. 3 Schistosome eggs involving the bladder wall.

Fig. 3 Schistosome eggs involving the bladder wall.
  • Park S, Reuter VE, Hansel DE

  • Histopathology. 2019 Jan;74(1):97-111.

2019-01-15

Fig. 1  Colonoscopy quality reporting by method. ADR indicates adenoma detection rate; NLP, natural language processing.

Fig. 1 Colonoscopy quality reporting by method. ADR indicates adenoma detection rate; NLP, natural language processing.
  • Lee JK, Jensen CD, Levin TR, Zauber AG, Doubeni CA, Zhao WK, Corley DA

  • J Clin Gastroenterol. 2019 Jan;53(1):e25-e30.

2019-01-16

Fig. 2 Molecular structure of methyl spiro-2,6-dioxopyrazine UVM147 based on X-ray crystallographic analysis.

Fig. 2 Molecular structure of methyl spiro-2,6-dioxopyrazine UVM147 based on X-ray crystallographic analysis.
  • Uprety R, Váradi A, Allaoa A, Redel-Traub GN, Palmer TC, Feinberg EN, Ferris AC, Pande VS, Pasternak GW, Majumdar S

  • Eur J Med Chem. 2018 Dec 22;164:241-251.

2019-01-17

Fig. 1 Representative subject 19 FDG-PET/CT coronal maximum intensity projection (MIP) images before (left) and 30 days after (right) CTL019 CAR-T cell immunotherapy demonstrating interval complete.

Fig. 1 Representative subject 19 FDG-PET/CT coronal maximum intensity projection (MIP) images before (left) and 30 days after (right) CTL019 CAR-T cell immunotherapy demonstrating interval complete.
  • Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J

  • Cytotherapy. 2018 Dec;20(12):1415-1418.

2019-01-18

Fig. 2 Identified dose-volume histogram thresholds for the 5 gastrointestinal symptoms after external beam radiation therapy alone for which the quantitative synthesis was considered.

Fig. 2 Identified dose-volume histogram thresholds for the 5 gastrointestinal symptoms after external beam radiation therapy alone for which the quantitative synthesis was considered.
  • Olsson CE, Jackson A, Deasy JO, Thor M

  • Int J Radiat Oncol Biol Phys. 2018 Aug 17. pii: S0360-3016(18)33546-6.

2019-01-21

Fig. 4 Immunochemistry for glypican‐3 highlights yolk sac tumour in a mixed tumour with embryonal carcinoma.

Fig. 4 Immunochemistry for glypican‐3 highlights yolk sac tumour in a mixed tumour with embryonal carcinoma.
  • Berney DM, Comperat E, Feldman DR, Hamilton RJ, Idrees MT, Samaratunga H, Tickoo SK, Yilmaz A, Srigley JR

  • Histopathology. 2019 Jan;74(1):171-183.

2019-01-22

Blood Journal, American Society of Hematology

Blood Journal, American Society of Hematology
  • Sarraf Yazdy M, Mato AR, Cheson BD

  • Blood. 2019 Jan 10;133(2):121-129.

2019-01-23

Fig. 1 Circulation of common respiratory viruses in a large geographic area within the Northern Hemisphere.

Fig. 1 Circulation of common respiratory viruses in a large geographic area within the Northern Hemisphere.
  • Charlton CL, Babady E, Ginocchio CC, Hatchette TF, Jerris RC, Li Y, Loeffelholz M, McCarter YS, Miller MB, Novak-Weekley S, Schuetz AN, Tang YW, Widen R, Drews SJ

  • Clin Microbiol Rev. 2018 Dec 12;32(1). pii: e00042-18.

2019-01-24

Fig. 1 Oncogenic mutant allele imbalance in advanced cancers.

Fig. 1 Oncogenic mutant allele imbalance in advanced cancers.
  • Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, Berger MF, Taylor BS

  • Cancer Cell. 2018 Nov 12;34(5):852-862.e4.

2019-01-25

Fig. 1 The dietary supplement CHSA selectively promotes BRAF V600E-positive melanoma PDX tumor growth in the presence of PTEN.

Fig. 1 The dietary supplement CHSA selectively promotes BRAF V600E-positive melanoma PDX tumor growth in the presence of PTEN.
  • Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J

  • Mol Cell. 2018 Mar 15;69(6):923-937.e8.

2019-01-28

Fig. 1 Predicted Impact of Events Score–Revised score from logistic regression by Hospital Anxiety and Depression Scale score, adjusted for multiple respondents.

Fig. 1 Predicted Impact of Events Score–Revised score from logistic regression by Hospital Anxiety and Depression Scale score, adjusted for multiple respondents.
  • Wendlandt B, Ceppe A, Choudhury S, Nelson JE, Cox CE, Hanson LC, Danis M, Tulsky JA, Carson SS

  • Ann Am Thorac Soc. 2018 Dec;15(12):1451-1458.

2019-01-29

Fig. 2 Ablation devices commonly used.

Fig. 2 Ablation devices commonly used.
  • Cornelis FH, Solomon SB

  • J Nucl Med. 2018 Dec;59(12):1801-1808.

2019-01-30

Fig. 1 Immunotherapeutic targets in urothelial malignancies.

Fig. 1 Immunotherapeutic targets in urothelial malignancies.
  • Iyer G, Rosenberg JE

  • Ann Oncol. 2018 Dec 1;29(12):2302-2312.

2019-01-31

Fig. 1 Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor regression.

Fig. 1 Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor regression.
  • Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM

  • Ann Oncol. 2018 Aug 1;29(8):1853-1860.

2019-02-01

Fig. 1 Clinical Pattern of Acquired Resistance.

Fig. 1 Clinical Pattern of Acquired Resistance.
  • Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA Jr, O'Reilly EM

  • J Immunother Cancer. 2018 Nov 20;6(1):127.
Open Access button